Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05046821 · ClinicalTrials.gov registry record

Sporadic Inclusion Body Myositis Natural History Study

A clinical trial of Inclusion Body Myositis and Sporadic Inclusion Body Myositis, sponsored by University of California, Irvine.

Active
Registry status
150
Enrollment target
13
Study locations

NCT05046821: Active study of Inclusion Body Myositis and Sporadic Inclusion Body Myositis, sponsored by University of California, Irvine.

NCT05046821 is a study of Inclusion Body Myositis and Sporadic Inclusion Body Myositis that is active but no longer recruiting, run by University of California, Irvine. The registered enrollment target is 150 participants, below the 221-participant average among 10 other Inclusion Body Myositis trials with a reported enrollment target (32% lower). The trial reports 13 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05046821, a study of Inclusion Body Myositis and Sporadic Inclusion Body Myositis, is active but no longer recruiting, sponsored by University of California, Irvine.

ACTIVE NOT RECRUITING
Registry status
150 participants
Enrollment target
13
Study locations

Study Summary

This is a prospective natural history study on patients with clinically defined sIBM. Participants will be assessed every 6 months over two years (five visits total). We will include 150 participants, enrolled across 13 sites, with sporadic IBM, diagnosed according to established criteria.

Primary Outcome

The IBMFRS is a 10 item questionnaire. Scores for each item range from 0 to 4. There is a total maximum score of 40 and minimum score of 0. The higher the score the better functional status of the person.

Study Locations (13)

California

  • University of California, Los Angeles - Los Angeles
  • University of California, Irvine - Orange

Colorado

  • University of Colorado - Aurora

Florida

  • University of Miami - Miami

Kansas

  • Kansas University Medical Center - Fairway

Maryland

  • Johns Hopkins University - Baltimore

Massachusetts

  • Brigham and Women's Hospital - Boston

Missouri

  • Washington University in St. Louis - St Louis

Ohio

  • Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2021-10-11
Est. Completion 2027-03-31
University of California, Irvine

368 total trials

What the registry record for NCT05046821 still lists

NCT05046821 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 10 other Inclusion Body Myositis trials with a reported enrollment target (32% lower).

The record links to 2 conditions, with Inclusion Body Myositis appearing as the primary indexed condition, and to 0 interventions.

NCT05046821 lists 13 locations in 12 states (California, Colorado, Florida).

Frequently Asked Questions

What is clinical trial NCT05046821 about?

NCT05046821 is a clinical study titled "Sporadic Inclusion Body Myositis Natural History Study". This is a prospective natural history study on patients with clinically defined sIBM. Participants will be assessed every 6 months over two years (five visits total). We will include 150 participants, enrolled across 13 sites, with sporadic IBM, diagnosed according to established criteria.

What is the current status of trial NCT05046821?

This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2021-10-11. Estimated completion is 2027-03-31.

What conditions does trial NCT05046821 study?

This clinical trial studies the following conditions: Inclusion Body Myositis, Sporadic Inclusion Body Myositis.

Who is sponsoring clinical trial NCT05046821?

This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05046821 being conducted?

This trial has 13 study locations across California, Colorado, Florida, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Inclusion Body Myositis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05046821's enrollment target sits among peer trials

150 3rd of 10 higher than 8 of 10 other Inclusion Body Myositis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Inclusion Body Myositis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05046821, the US trial registry maintained by the National Library of Medicine. NCT05046821 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.